Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ACP-211 · 1 trial · 2 indications
The MADRS is a clinician-rated scale that assesses the severity of depressive symptoms. It consists of 10 items, each scored from 0 (no symptoms) to 6 (severe symptoms), resulting in a total score range of 0 to 60. Higher scores indicate greater depression severity.
| Arm | Type | Description |
|---|---|---|
| ACP-211 600 mg | EXPERIMENTAL | ACP-211 600 mg, administered orally twice weekly |
| ACP-211 300 mg | EXPERIMENTAL | ACP-211 300 mg, administered orally twice weekly |
| Placebo | PLACEBO_COMPARATOR | Matching placebo, administered orally twice weekly |
| Name | Type | Description |
|---|---|---|
| ACP-211 | DRUG | ACP-211 monotherapy |
| Placebo | DRUG | Placebo control |
Inclusion Criteria: * Adults ≥18 and ≤65 years of age * Provides written informed consent * Clinical diagnosis of MDD * History of inadequate response to at least two antidepressants, with at least one inadequate response documented during the current episode * Currently treated with an approved an...
Top 20 of 31 competitors
ACP-211 is an investigational small molecule being developed for Major Depressive Disorder (MDD). It is currently being studied as a monotherapy in patients with MDD who have had an inadequate response to prior antidepressant treatment. The drug is in Phase 2 clinical development and has not been approved by regulatory authorities.
ACP-211 targets the NMDA receptor, a molecular target involved in the pathophysiology of depression. By modulating NMDA receptor activity, the drug is being investigated for its potential to treat Major Depressive Disorder. This mechanism is being evaluated in a Phase 2 clinical trial for patients with inadequate antidepressant response.
ACP-211 is being developed by ACADIA Pharmaceuticals Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol ACAD. The company is currently conducting a Phase 2 clinical trial to evaluate the drug as a monotherapy for Major Depressive Disorder in patients who have not responded adequately to existing antidepressants.
ACP-211 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The ongoing Phase 2 trial is recruiting participants to evaluate the drug's efficacy and safety as a monotherapy for Major Depressive Disorder with inadequate antidepressant response.
ACP-211 is being evaluated in one Phase 2 clinical trial with the identifier NCT07284667. This randomized, double-blind, placebo-controlled study is recruiting 153 participants in the United States. The trial is investigating ACP-211 monotherapy for Major Depressive Disorder in adults aged 18 years and older who have had an inadequate response to antidepressants.